lanthanum carbonate (Fosrenol)

Following an abbreviated submission:

lanthanum carbonate oral powder (Fosrenol®) is accepted for restricted use in NHS Scotland.

Indication under review: as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD).

Lanthanum is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels  1.78 mmol/L in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

SMC restriction: as a second-line agent in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or CAPD where a non-aluminium, non-calcium phosphate binder is required.

Lanthanum carbonate is as effective as calcium carbonate in reducing phosphate to target levels.